Form 4: MaxCyte Director John Johnston Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. (MXCT) on December 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On December 26, 2024, John Johnston, a director of MaxCyte, Inc. (MXCT), executed a stock option to purchase 3,000 shares of common stock at a price of $2.932 per share.
• Simultaneously, Johnston sold 3,000 shares of common stock at a weighted average price of $4.007, with individual sales ranging from $3.995 to $4.06.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on December 19, 2023.
• Following these transactions, Johnston directly owns 141,950 shares of MaxCyte common stock and 20,417 stock options.
• The stock option is fully vested and exercisable, with an expiration date of July 18, 2028.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine insider trading activity under a pre-arranged plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors, which is important for investors to assess management's confidence in the company's prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The use of a 10b5-1 trading plan is a common method for insiders to sell shares without raising concerns about trading on non-public information, similar to practices seen at companies like CRISPR Therapeutics and Editas Medicine.
• The size of the transaction is relatively small, suggesting it is part of a planned diversification strategy rather than a reaction to specific company events.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it represents a small percentage of the outstanding shares.
• The use of a 10b5-1 plan ensures transparency and reduces the risk of insider trading concerns.

Key Dates